Update on Nasdaq initial public offering in the United States
As announced on 18 August 2021, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’) filed a registration statement on… Read more
Harvest Launches Equity Raising to Pursue Strategic Growth
Harvest Technology Group Limited (ASX:HTG) (“Harvest”, “Company”, “Group” or “HTG”) is pleased to announce the following: • Harvest continues to… Read more
HTG Investor Presentation
Harvest Technology Group Equity Raising December 2021
Nyrada Inc Annual General Meeting Presentation
“Our strategy is to advance highly optimised drug candidates towards a key value inflection point , such as an efficacy… Read more
Nyrada AGM 2021 Chairman’s Address
“Looking forward, we expect Phase I studies for both the Cholesterol-Lowering and Brain Injury Programs will commence in the second… Read more
MoneyTalks: Canary Capital’s Paul Hart is bullish about the biotech sector – here’s why
Paul Hart was interviewed by Stockhead regarding the Biotech Sector. Please see below the article published November 5th, 2021. MoneyTalks… Read more
Incannex September 2021 Quarterly Activities Report and Appendix 4C
Highlights: • Phase 2a psilocybin-assisted therapy for Generalised Anxiety Disorder clinical trial has received approval to proceed from the Monash… Read more
HTG Annual Report 2021
FY2021 Highlights Key priorities for the Group during FY2021 were to build on momentum with a new pipeline of vessel… Read more
Positive pre-IND meeting with US FDA and ethics approval to commence Phase 2a Psi-GAD clinical trial: psilocybin-assisted psychotherapy for Generalised Anxiety Disorder
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce: 1. that… Read more
